Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:
-- The first section of this topic is shown below --
- Active tuberculosis (TB)
- Primary infection or reactivation of latent infection
- Without preventive therapy, affects 10% of infected individuals
- Risk increases with immunosuppression: Highest risk first 2 years after infection. Reactivation risk increases with comorbidities (e.g., HIV, diabetes).
- Well-described forms: pulmonary (85% of cases), miliary (disseminated), meningeal, abdominal, lymphadenitis (scrofula)
- Usually acquired by inhalation of airborne bacilli from an individual with active TB. Bacilli multiply in alveoli and spread via macrophages, lymphatics, and blood. Three possible outcomes:
- Eradication: Tissue hypersensitivity halts infection within 10 weeks.
- Primary TB
- Latent TB (See “Tuberculosis, Latent [LTBI].”)
- Children have a faster rate of progression to disease, higher risk of progression to disease, and more commonly have severe disease.
- Most children with pulmonary TB are asymptomatic.
- Pediatric TB treatment should be directly observed (directly observed therapy [DOT]) using four drugs.
- Worldwide (2016): 10.4 million: 133 cases/100,000 population; highest incidence in Asia and Africa (1)
- United States (2014): 9,421 (3/100,000); incidence in foreign-born persons 14 times that of U.S.-born persons (2)
Worldwide (2016): Indirect estimates are uncertain due to variance in reporting systems. Higher burden countries have approximately 150 cases/100,000 population (2).
Worldwide (2015): 1.4 million deaths due to TB, 1 of the top 10 causes of death worldwide
Etiology and Pathophysiology
- Mycobacterium tuberculosis, Mycobacterium bovis, or Mycobacterium africanum are causative organisms.
- Cell-mediated response by activated T lymphocytes and macrophages forms a granuloma that limits bacillary replication. Destruction of the macrophages produces early “solid necrosis.” In 2 to 3 weeks, “caseous necrosis” develops and LTBI ensues. In the immunocompetent, granuloma undergoes “fibrosis” and calcification. In the immunocompromised, primary progressive TB develops. Cavitary lesions may form. Necrotic lesions may rupture into bronchioles with resulting aerosolization of tuberculous bacilli.
- For infection: homeless, ethnic minorities, close quarters (correctional facilities, nursing homes, barracks), close contact with infected person, living in areas with high incidence of active TB, health care workers; medically underserved, low income, substance abuse
- For development of disease once infected: HIV; lymphoma; silicosis; diabetes mellitus; chronic renal failure; cancer of head, neck, or lung; children <5 years of age; malnutrition; systemic corticosteroids, immunosuppressive drugs; IV drug abuse, alcohol abuse, cigarette smokers; <2 years since infection with M. tuberculosis; history of gastrectomy or jejunal bypass; <90% of ideal body weight
- Screen for and treat LTBI. Report active TB to health department; test and treat all close contacts.
- Bacillus Calmette-Guérin (BCG) vaccine: Live attenuated M. bovis prevents 50% of pulmonary disease and 80% of meningitis and miliary disease in children. Relatively ineffective in adults. Use is more common in endemic countries. In the United States, consider BCG for high-risk children with negative PPD and HIV tests or for health workers at risk for drug-resistant infection.
Commonly Associated Conditions
Immunosuppression; HIV-coinfection; malignancy